Market Data graphic

Sciences biologiques

Vous êtes ici

Le secteur des sciences biologiques comprend des sociétés dont les activités concernent les produits biopharmaceutiques, la fabrication et la distribution médicale et les produits biologiques.

EXMceuticals ("EXM") est une société de biosciences qui croit fermement aux bienfaits potentiels du chanvre et du cannabis pour la santé et le bien-être. EXM est un acteur émergent sur le marché, avec l'ambition de devenir l'un des fournisseurs mondiaux d'ingrédients de cannabis de la meilleure qualité. EXM est en train de créer une installation d'extraction et de raffinage à l'échelle industrielle, conforme aux BPF et de qualité pharmaceutique, au sein de l'Union européenne, près de Lisbonne au Portugal. EXM dispose d'une installation de recherche et développement et d'une raffinerie pilote de cannabis à Lisbonne, au Portugal. EXM vise le marché B2B et fournira des ingrédients purs à l'industrie pharmaceutique, médicale et du bien-être.

Field Trip est un leader mondial dans le développement et la prestation de thérapies psychédéliques. Avec Field Trip Discovery, la division de recherche de la société, menant le développement de la prochaine génération de molécules psychédéliques et menant des recherches avancées sur les psychédéliques à base de plantes, les cliniques Field Trip Health pour les thérapies psychédéliques opérant et ouvrant en Amérique du Nord et Field Trip Digital, la société Division de la technologie, en développant les outils numériques et technologiques pour soutenir les expériences psychédéliques et l'expansion de la conscience, nous aidons les gens, des personnes en traitement à celles qui recherchent une croissance personnelle accélérée, avec un moyen simple et fondé sur des preuves pour guérir et intensifier leur engagement avec le monde.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery, the Company’s research division, leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health clinics for psychedelic therapies operating and opening within North America and Field Trip Digital, the Company’s technology division, building the digital and technological tools to support psychedelic experiences and consciousness expansion, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

FinCanna Capital Corp. est une société de redevances pour l'industrie du cannabis médical sous licence, qui investit dans des entreprises de premier ordre importantes et évolutives. L'objectif commercial de l'Emetteur est de fournir des solutions capitales aux entreprises de l'industrie du cannabis médical avec un potentiel important, un opérateur hautement qualifié et expérimenté, qui projette de produire des produits médicaux sous licence à forte valeur ajoutée ou des produits et services connexes.

Marapharm intends to pursue commercial ventures in the medical marijuana business. We were established to enter the emerging market created by Canada’s Marihuana for Medical Purposes Regulations (“MMPR”). The Company is positioned as a pioneer and leader in this marketplace with plans to construct brand new facilities in British Columbia’s Okanagan Valley and rapidly expand them to meet strategic advantages for growth and market penetration. Our license is currently under review. Plans call for initial construction of a facility on 11 acres under lease to us with expansion plans to a 100,000 sq. foot facility in year two. Further construction is built into the Company’s long term growth strategy once a realistic assessment and export demand can be determined. Additional facility footage will at that point be brought forward. The Canadian market potential for medical marijuana is currently estimated at Cdn. $1.2 billion and the world market potential is estimated at Cdn. $115 billion. As a result, Marapharm is well positioned to enjoy significant and consistent revenue growth for many years.

Flower One is sharply focused on quickly becoming the leading cannabis cultivator, producer and innovator in the highly lucrative Nevada market. Flower One owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms, and owns the established NLV Organics consumer brand of cannabis products. The Company is also rapidly converting its 455,000 square-foot greenhouse and production facility, which is the largest in the State of Nevada, for cultivating and processing high-quality cannabis at scale. Combined, the flagship greenhouse facility and production facility (once fully operational) and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. The Company is fully licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in the state of Nevada and currently holds licensing agreements with their Brand Partners, Flyte Concentrates, Rapid-Dose Therapeutics’ Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, G Pen and the The Medicine Cabinet.

Flower One is sharply focused on quickly becoming the leading cannabis cultivator, producer and innovator in the highly lucrative Nevada market. Flower One owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms, and owns the established NLV Organics consumer brand of cannabis products. The Company is also rapidly converting its 455,000 square-foot greenhouse and production facility, which is the largest in the State of Nevada, for cultivating and processing high-quality cannabis at scale. Combined, the flagship greenhouse facility and production facility (once fully operational) and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates and infused products. The Company is fully licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in the state of Nevada and currently holds licensing agreements with their Brand Partners, Flyte Concentrates, Rapid-Dose Therapeutics’ Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, G Pen and the The Medicine Cabinet.

Flower One is the largest cannabis cultivator, producer and full-service brand fulfillment partner in the state of Nevada. 

Flower One Holdings Inc. - Common Shares

Chaque bon de souscription donne à chaque porteur de bon de souscription le droit, lors de son exercice à tout moment après la date d'émission et avant l'heure d'expiration, d'acquérir une (1) action ordinaire au paiement du prix d'exercice de 0,36 $.

Voir l'acte de garantie pour plus de détails.

Flower One is the largest cannabis cultivator, producer and full-service brand fulfillment partner in the state of Nevada. Flower One's fully operational flagship 400,000 square-foot greenhouse and 55,000 square-foot production facility is used for cannabis cultivation, processing, production and manufacturing of dry flower, pre-rolls, cannabis oils, distillates, concentrates, edibles, topicals and infused products. The Company also operates a 25,000 square-foot indoor cultivation and production facility in North Las Vegas, with nine grow rooms, and a state of the art commercial kitchen that will produce several of the industry’s top performing edible brands. Leveraging its scale and more than 20 years of greenhouse operational excellence, Flower One offers consistent, reliable, high-volume, and just-in-time fulfillment to a growing number of established cannabis brands. The Company is fully licensed for both recreational and medical marijuana cultivation and production in the state of Nevada.

Advertisement

Publicité

Dernières nouvelles CSE

Évènements à venir

Advertisement

Publicité